Full-Time

Director – Distribution

Cooper Companies

Cooper Companies

201-500 employees

Global medical devices and vision care

Compensation Overview

$121.7k - $187.2k/yr

Rochester, NY, USA

In Person

Category
Operations & Logistics (2)
,
Required Skills
Inventory Management
Financial analysis
Excel/Numbers/Sheets
Requirements
  • Microsoft Office Suite with a proficiency in Excel
  • ERP systems and Warehouse Management systems experience
  • Project Management and Presentation skills
  • Extensive knowledge of current best practices for distribution and logistics
  • Strong communication, analytical, problem solving, team building and motivational skills
  • Experience in automated warehouse management and transportation management systems
  • Ability to empower the workforce and building strong teams
  • Excellent organization skills with a high degree of initiative and flexibility; ability to define performance measures directly related to business and hold people accountable for such
  • Ability to complete financial analysis and review, and analyze existing cost data
  • Must possess the traits of being proactive, risk taker, and change agent
  • Extensive knowledge of international shipping and export shipping requirements
  • 10+ years progressive management experience in a distribution, logistics and/or supply chain
  • 5+ years experience in contract negotiations in areas of freight and third party
  • 5+ years experience in international export
  • Bachelor's Degree in business management, engineering, or logistics
  • MBA preferred
  • Lean Management a plus
  • APICS Certification a plus
Responsibilities
  • Directs all activities connected with the receiving, picking, packing, and shipping of CooperVision products
  • Manage KPI’s to drive business performance ensuring alignment and deliverables to corporate strategies
  • Budgeting and P&L control
  • Develop and execute OpEx and CapEx budgets and forecasts in line with corporate goals
  • Engage and lead the team by defining criteria for excellence and improving core competencies. Improve existing employee skills sets in the areas of distribution and inventory control. Actively mentor and coach team to help support and further their professional growth and development
  • Establish and maintain meetings with commercial teams
  • Establish and maintain meetings with strategic customers to ensure the distribution center is delivering on service level agreements
  • International shipping and compliance experience
  • Responsible for documenting shipping contingency planning
  • Responsible for periodic customer visits
  • Responsible for strict adherence to FDA compliance, export compliance, safety as well as CooperVision policies and procedures including appropriate audit controls
  • Assure departmental adherence to Good Distribution Practices, Standard Operating Procedures (SOP) and ISO 9000 requirements
  • Responsible for developing/documenting shipping contingency planning
  • Manage employee relations and performance management
  • Provide ongoing communication regarding productivity status updates to the Sr. Director Distribution Americas
  • Ensure SOP development for inventory control is in compliance with corporate financial requirements
  • Ensure an understanding of the existing inventory management practices, reporting and requirements throughout the distribution center
  • Assist in the development of functional strategies and continuous improvement initiatives
  • Interact with internal and external leaders, including senior management
  • Partner with Environmental Health and Safety team to ensure high standards are in place for a safe working environment for all employees
  • Monitor and ensure all regulatory procedures are properly administered and within appropriate tolerances
  • Evaluate current procedures and practices for accomplishing department objectives
Desired Qualifications
  • MBA preferred
  • Lean Management a plus
  • APICS Certification a plus

Cooper Companies operates in two main areas: CooperVision and CooperSurgical. CooperVision makes a wide range of contact lenses to correct vision, supported by product development, manufacturing, and global distribution. CooperSurgical offers medical devices, fertility, and genomic products for women’s health, covering care from contraception through advanced reproductive treatments, with a vertically integrated model that controls research, development, manufacturing, and distribution. Compared with competitors, the company combines vision care and women’s health in one group and maintains end-to-end control of its product lifecycle, enabling integrated supply and service delivery to healthcare providers and patients worldwide. Its goal is to improve health outcomes for people through accessible contact lenses and comprehensive women’s health products and services, across the globe.

Company Size

201-500

Company Stage

IPO

Headquarters

Pleasanton, California

Founded

1958

Simplify Jobs

Simplify's Take

What believers are saying

  • Premium lens adoption drove Q4 and Q1 2026 growth and market-share gains.
  • EMEA revenue reached $289.7 million in April 2026, supporting international expansion.
  • Management raised 2026 guidance, reflecting improving margins and stronger free-cash-flow generation.

What critics are saying

  • Japan's legacy hydrogel lens declines continue to pressure CooperVision growth.
  • Asia Pacific revenue missed expectations, signaling weaker execution in a key region.
  • Fertility demand and reimbursement cycles can disrupt CooperSurgical's revenue and margin support.

What makes Cooper Companies unique

  • Two-unit model spans vision care and women's health across CooperVision and CooperSurgical.
  • CooperVision leads soft contact lenses, including premium MyDay and MyDay MiSight products.
  • Global footprint reaches over 130 countries, with more than 15,000 employees.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Cooper Companies who can refer or advise you

Benefits

Paid Vacation

Performance Bonus

Health Insurance

401(k) Retirement Plan

Life Insurance

Wellness Program

Professional Development Budget

Company News

Oregon Capital Insider
May 4th, 2026
CooperCompanies appoints Paul Keel to its Board of Directors.

CooperCompanies appoints Paul Keel to its Board of Directors. GlobeNewswire | CooperCompanies Yesterday at 1:15pm PDT SAN RAMON, Calif., May 04, 2026 (GLOBE NEWSWIRE) - CooperCompanies (Nasdaq: COO), a leading global medical device company, announced today that its Board of Directors has appointed Paul Keel as an independent director, effective July 1, 2026. Mr. Keel has also been appointed to serve on the Audit Committee when he joins the Board. "We are delighted to welcome Paul to our Board as a new Director," said Colleen Jay, Chair of the Board of CooperCompanies. "His experience as a CEO in the medical device sector, along with a successful track record of leading complex global operations, will be a significant asset as Cooper continues to execute its strategy and create long-term value for patients, customers, and shareholders." Mr. Keel has served as President and Chief Executive Officer of Envista Holdings Corporation (NYSE: NVST), a global specialty medical technology company, since 2024. Prior to joining Envista, Mr. Keel served as CEO of Smiths Group plc (LON: SMIN), a diversified global industrial technology company and FTSE constituent, from 2021 to 2024. Earlier, he spent 16 years at 3M, serving in various leadership roles, including Group President of 3M Consumer Business, President of 3M Medical, President of 3M Unitek, SVP of Manufacturing & Supply Chain, and SVP of Marketing, Sales & Business Development. Mr. Keel's career also includes roles at General Mills, General Electric, Norwest Equity Partners, and McKinsey & Company. He holds an MBA from Harvard Business School and a BA in Economics from Carleton College. About CooperCompanies CooperCompanies (Nasdaq: COO) is a leading global medical device company focused on helping people experience life's beautiful moments through its two business units, CooperVision and CooperSurgical. CooperVision is a trusted leader in the contact lens industry, helping to improve the way people see each day. CooperSurgical is a leading fertility and women's healthcare company dedicated to putting time on the side of women, babies, and families at the healthcare moments that matter most. Headquartered in San Ramon, CA, CooperCompanies has a workforce of more than 15,000, sells products in over 130 countries, and positively impacts over fifty million lives each year. For more information, please visit www.coopercos.com. Forward-Looking Statements This press release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Statements relating to the Company's efforts to enhance long-term shareholder value, plans, strategies, future actions, and other statements of which are other than statements of historical fact, are forward-looking. Forward-looking statements necessarily depend on assumptions, data, or methods that may be incorrect or imprecise and are subject to risks and uncertainties. Statements regarding future events and performance and contain words such as "expects" and similar words or phrases. A wide range of factors could materially affect future developments, including, but not limited to, uncertainties related to market conditions and other factors set forth in its other filings with the United States Securities and Exchange Commission, including its most recent Annual Report on Form 10-K. These risks and uncertainties may cause actual future results or actions to be materially different than those expressed in such forward-looking statements. Oregon Capital Insider do not intend, or undertake any duty, to update any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. Kim Duncan Vice President, Investor Relations and Risk Management 925-460-3663 This is a paid placement. For further inquiries, please contact GlobeNewswire directly.

Yahoo Finance
Apr 8th, 2026
Cooper Companies shares drop 17% in 3 months amid valuation debate at $13.7B market cap

Cooper Companies has raised $120 million in a Series C round, valuing the healthcare company at $1.45 billion, as shares face recent pressure with declines of 9% over the past month and roughly 17% over three months. The company operates two main businesses: CooperVision, generating revenue of $2.79 billion from contact lenses, and CooperSurgical, contributing $1.36 billion from women's and family health products. Total annual revenue reached $4.15 billion with net income of $401.4 million. Recent analysis suggests the stock may be 24.1% undervalued at its current price of $69.66, with a fair value estimate of $91.80. Management projects approximately $2 billion in free cash flow over the next three years as capital expenditure cycles wind down.

Yahoo Finance
Mar 25th, 2026
CooperCompanies Q4 revenue hits $1.02B, raises full-year earnings guidance

CooperCompanies reported Q4 revenues of $1.02 billion, up 6.2% year on year, meeting analysts' expectations. The medical devices manufacturer, which focuses on vision care and women's health products, delivered an impressive beat on full-year earnings per share guidance, though organic revenue was in line with estimates. The company raised both earnings and free cash flow guidance following strong profitability and cash generation. Operating margins exceeded expectations due to synergies from last year's reorganisation. President and CEO Al White highlighted momentum from product launches, including the premium MyDay portfolio and early traction from MyDay MiSight. Across the medical devices and supplies sector, six tracked companies reported mixed Q4 results, with revenues collectively beating consensus estimates by 1.9%. Share prices have declined 9.5% on average since earnings announcements.

Yahoo Finance
Mar 17th, 2026
Cooper Companies down 21% from 52-week high despite beating Q1 earnings estimates

Cooper Companies, a California-based medical devices manufacturer, has declined 12.5% over the past 52 weeks, underperforming the Dow Jones Industrial Average's 13.2% gain during the same period. The company, valued at $13.9 billion, has fallen 20.9% from its December 2025 peak of $89.83. Shares dropped 2.2% on 5 March following mixed Q1 2026 results. Whilst revenue rose 6% year-over-year to $1 billion and adjusted earnings per share increased 20% to $1.10, both beating estimates, investors focussed on weak organic revenue growth and challenges in the Asia Pacific region. The stock has traded below its 200-day and 50-day moving averages since early March. Despite the decline, analysts maintain a "Moderate Buy" rating with a mean price target of $90.81, suggesting 27.8% upside potential.

Yahoo Finance
Mar 12th, 2026
Needham raises Cooper Companies price target to $101, maintains buy rating after strong Q1 results

Needham raised its price target on The Cooper Companies (NASDAQ: COO) to $101 from $99, maintaining a Buy rating. The firm cited solid first-quarter results, improving end markets and operating efficiencies supporting margin expansion. Barclays also increased its target to $103 from $98 with an Overweight rating, noting improving sequential growth in Vision and Surgical segments offsetting declines in older hydrogel products in Japan. Cooper Companies reported first-quarter non-GAAP earnings per share of $1.10, beating the $1.03 consensus estimate, with revenue of $1.024 billion versus $1.02 billion expected. CEO Al White highlighted growth in the MyDay portfolio and benefits from last year's reorganisation. The company develops and markets products for contact lens wearers through its CooperVision and CooperSurgical segments.